Circulating miRNA Expression Profiling and Target Prediction in Patients Receiving Dexmedetomidine

Xuehui Yang, Hongmei Chen, Yan Chen, Yochai Birnbaum, Rongbi Liang, Yumei Ye, Jinqiao Qian

Research output: Contribution to journalArticle

Abstract

Background/Aims: Circulating miRNAs could serve as biomarkers for diagnosis or prognosis of heart diseases and cerebrovascular diseases. Dexmedetomidine has protective effects in various organs. The effects of dexmedetomidine on circulating miRNAs remain unknown. Here, we investigated differentially expressed miRNA and to predict the target genes of the miRNA in patients receiving dexmedetomidine. Methods: The expression levels of circulating miRNAs of 3 patients were determined through high through-put miRNA sequencing technology. Target genes of the identified differentially expressed miRNAs were predicted using TargetScan 7.1 and miRDB v.5. Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to conduct functional annotation and pathway enrichment analysis of target genes respectively. Results: Twelve differentially expressed miRNAs were identified. Five miRNAs were upregulated (hsa-miR-4508, hsa-miR-novel-chr8-87373, hsa-miR-30a-3p, hsa-miR-novel-chr16-26099, hsa-miR-4306) and seven miRNAs (hsa-miR-744-5p, hsa-miR-320a, hsa-miR-novel-chr9-90035, hsa-miR-101-3p, hsa-miR-150-5p, hsa-miR-342-3p, and hsa-miR-140-3p) were downregulated after administration of dexmedetomidine in the subjects. The target genes and pathways related to the differentially expressed miRNAs were predicted and analyzed. Conclusion: The differentially expressed miRNAs may be involved in the mechanisms of action of dexmedetomidine. Specific miRNAs, such as hsa-miR-101-3p, hsa-miR-150-5p and hsa-miR-140-3p, are new potential targets for further functional studies of dexmedetomidine.

Original languageEnglish (US)
Pages (from-to)552-568
Number of pages17
JournalCellular Physiology and Biochemistry
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Dexmedetomidine
MicroRNAs
Genes
Encyclopedias
Cerebrovascular Disorders
Gene Ontology

Keywords

  • Cardioprotection
  • Circulating miRNAs
  • Dexmedetomidine
  • Expression profiling
  • Ischemia/reperfusion injury

ASJC Scopus subject areas

  • Physiology

Cite this

Circulating miRNA Expression Profiling and Target Prediction in Patients Receiving Dexmedetomidine. / Yang, Xuehui; Chen, Hongmei; Chen, Yan; Birnbaum, Yochai; Liang, Rongbi; Ye, Yumei; Qian, Jinqiao.

In: Cellular Physiology and Biochemistry, 01.01.2018, p. 552-568.

Research output: Contribution to journalArticle

Yang, Xuehui ; Chen, Hongmei ; Chen, Yan ; Birnbaum, Yochai ; Liang, Rongbi ; Ye, Yumei ; Qian, Jinqiao. / Circulating miRNA Expression Profiling and Target Prediction in Patients Receiving Dexmedetomidine. In: Cellular Physiology and Biochemistry. 2018 ; pp. 552-568.
@article{f679db6fd6d34fb3b5f632fbf60498ee,
title = "Circulating miRNA Expression Profiling and Target Prediction in Patients Receiving Dexmedetomidine",
abstract = "Background/Aims: Circulating miRNAs could serve as biomarkers for diagnosis or prognosis of heart diseases and cerebrovascular diseases. Dexmedetomidine has protective effects in various organs. The effects of dexmedetomidine on circulating miRNAs remain unknown. Here, we investigated differentially expressed miRNA and to predict the target genes of the miRNA in patients receiving dexmedetomidine. Methods: The expression levels of circulating miRNAs of 3 patients were determined through high through-put miRNA sequencing technology. Target genes of the identified differentially expressed miRNAs were predicted using TargetScan 7.1 and miRDB v.5. Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to conduct functional annotation and pathway enrichment analysis of target genes respectively. Results: Twelve differentially expressed miRNAs were identified. Five miRNAs were upregulated (hsa-miR-4508, hsa-miR-novel-chr8-87373, hsa-miR-30a-3p, hsa-miR-novel-chr16-26099, hsa-miR-4306) and seven miRNAs (hsa-miR-744-5p, hsa-miR-320a, hsa-miR-novel-chr9-90035, hsa-miR-101-3p, hsa-miR-150-5p, hsa-miR-342-3p, and hsa-miR-140-3p) were downregulated after administration of dexmedetomidine in the subjects. The target genes and pathways related to the differentially expressed miRNAs were predicted and analyzed. Conclusion: The differentially expressed miRNAs may be involved in the mechanisms of action of dexmedetomidine. Specific miRNAs, such as hsa-miR-101-3p, hsa-miR-150-5p and hsa-miR-140-3p, are new potential targets for further functional studies of dexmedetomidine.",
keywords = "Cardioprotection, Circulating miRNAs, Dexmedetomidine, Expression profiling, Ischemia/reperfusion injury",
author = "Xuehui Yang and Hongmei Chen and Yan Chen and Yochai Birnbaum and Rongbi Liang and Yumei Ye and Jinqiao Qian",
year = "2018",
month = "1",
day = "1",
doi = "10.1159/000494168",
language = "English (US)",
pages = "552--568",
journal = "Cellular Physiology and Biochemistry",
issn = "1015-8987",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Circulating miRNA Expression Profiling and Target Prediction in Patients Receiving Dexmedetomidine

AU - Yang, Xuehui

AU - Chen, Hongmei

AU - Chen, Yan

AU - Birnbaum, Yochai

AU - Liang, Rongbi

AU - Ye, Yumei

AU - Qian, Jinqiao

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background/Aims: Circulating miRNAs could serve as biomarkers for diagnosis or prognosis of heart diseases and cerebrovascular diseases. Dexmedetomidine has protective effects in various organs. The effects of dexmedetomidine on circulating miRNAs remain unknown. Here, we investigated differentially expressed miRNA and to predict the target genes of the miRNA in patients receiving dexmedetomidine. Methods: The expression levels of circulating miRNAs of 3 patients were determined through high through-put miRNA sequencing technology. Target genes of the identified differentially expressed miRNAs were predicted using TargetScan 7.1 and miRDB v.5. Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to conduct functional annotation and pathway enrichment analysis of target genes respectively. Results: Twelve differentially expressed miRNAs were identified. Five miRNAs were upregulated (hsa-miR-4508, hsa-miR-novel-chr8-87373, hsa-miR-30a-3p, hsa-miR-novel-chr16-26099, hsa-miR-4306) and seven miRNAs (hsa-miR-744-5p, hsa-miR-320a, hsa-miR-novel-chr9-90035, hsa-miR-101-3p, hsa-miR-150-5p, hsa-miR-342-3p, and hsa-miR-140-3p) were downregulated after administration of dexmedetomidine in the subjects. The target genes and pathways related to the differentially expressed miRNAs were predicted and analyzed. Conclusion: The differentially expressed miRNAs may be involved in the mechanisms of action of dexmedetomidine. Specific miRNAs, such as hsa-miR-101-3p, hsa-miR-150-5p and hsa-miR-140-3p, are new potential targets for further functional studies of dexmedetomidine.

AB - Background/Aims: Circulating miRNAs could serve as biomarkers for diagnosis or prognosis of heart diseases and cerebrovascular diseases. Dexmedetomidine has protective effects in various organs. The effects of dexmedetomidine on circulating miRNAs remain unknown. Here, we investigated differentially expressed miRNA and to predict the target genes of the miRNA in patients receiving dexmedetomidine. Methods: The expression levels of circulating miRNAs of 3 patients were determined through high through-put miRNA sequencing technology. Target genes of the identified differentially expressed miRNAs were predicted using TargetScan 7.1 and miRDB v.5. Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to conduct functional annotation and pathway enrichment analysis of target genes respectively. Results: Twelve differentially expressed miRNAs were identified. Five miRNAs were upregulated (hsa-miR-4508, hsa-miR-novel-chr8-87373, hsa-miR-30a-3p, hsa-miR-novel-chr16-26099, hsa-miR-4306) and seven miRNAs (hsa-miR-744-5p, hsa-miR-320a, hsa-miR-novel-chr9-90035, hsa-miR-101-3p, hsa-miR-150-5p, hsa-miR-342-3p, and hsa-miR-140-3p) were downregulated after administration of dexmedetomidine in the subjects. The target genes and pathways related to the differentially expressed miRNAs were predicted and analyzed. Conclusion: The differentially expressed miRNAs may be involved in the mechanisms of action of dexmedetomidine. Specific miRNAs, such as hsa-miR-101-3p, hsa-miR-150-5p and hsa-miR-140-3p, are new potential targets for further functional studies of dexmedetomidine.

KW - Cardioprotection

KW - Circulating miRNAs

KW - Dexmedetomidine

KW - Expression profiling

KW - Ischemia/reperfusion injury

UR - http://www.scopus.com/inward/record.url?scp=85054995740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054995740&partnerID=8YFLogxK

U2 - 10.1159/000494168

DO - 10.1159/000494168

M3 - Article

SP - 552

EP - 568

JO - Cellular Physiology and Biochemistry

JF - Cellular Physiology and Biochemistry

SN - 1015-8987

ER -